Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease
- PMID:33364854
- PMCID: PMC7751789
- DOI: 10.2147/JEP.S259328
Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease
Abstract
Introduction: Inhaled β-agonists have been foundational medications for maintenance COPD management for decades. Through activation of cyclic adenosine monophosphate pathways, these agents relax airway smooth muscle and improve expiratory airflow by relieving bronchospasm and alleviating air trapping and dynamic hyperinflation improving breathlessness, exertional capabilities, and quality of life. β-agonist drug development has discovered drugs with increasing longer durations of action: short acting (SABA) (4-6 h), long acting (LABA) (6-12 h), and ultra-long acting (ULABA) (24 h). Three ULABAs, indacaterol, olodaterol, and vilanterol, are approved for clinical treatment of COPD.
Purpose: This article reviews both clinically approved ULABAs and ULABAs in development.
Conclusion: Indacaterol and olodaterol were originally approved for clinical use as monotherapies for COPD. Vilanterol is the first ULABA to be approved only in combination with other respiratory medications. Although there are many other ULABA's in various stages of development, most clinical testing of these novel agents is suspended or proceeding slowly. The three approved ULABAs are being combined with antimuscarinic agents and corticosteroids as dual and triple agent treatments that are being tested for clinical use and efficacy. Increasingly, these clinical trials are using specific COPD clinical characteristics to define study populations and to begin to develop therapies that are trait-specific.
Keywords: COPD; LABA; ULABA; chronic obstructive pulmonary disease; long-acting β-agonist; ultra long-acting β-agonist; β-agonist.
© 2020 Burkes and Panos.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Similar articles
- Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.Kew KM, Dias S, Cates CJ.Kew KM, et al.Cochrane Database Syst Rev. 2014 Mar 26;2014(3):CD010844. doi: 10.1002/14651858.CD010844.pub2.Cochrane Database Syst Rev. 2014.PMID:24671923Free PMC article.Review.
- Update on ultra-long-acting β agonists in chronic obstructive pulmonary disease.Zafar MA, Droege C, Foertsch M, Panos RJ.Zafar MA, et al.Expert Opin Investig Drugs. 2014 Dec;23(12):1687-701. doi: 10.1517/13543784.2014.942730. Epub 2014 Aug 19.Expert Opin Investig Drugs. 2014.PMID:25139313Review.
- Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.Ismaila AS, Haeussler K, Czira A, Tongbram V, Malmenäs M, Agarwal J, Nassim M, Živković-Gojović M, Shen Y, Dong X, Duarte M, Compton C, Vogelmeier CF, Halpin DMG.Ismaila AS, et al.Adv Ther. 2022 Nov;39(11):4961-5010. doi: 10.1007/s12325-022-02234-x. Epub 2022 Jul 20.Adv Ther. 2022.PMID:35857184Free PMC article.
- Long-acting beta-agonists and their association with inhaled corticosteroids in COPD.Fuso L, Mores N, Valente S, Malerba M, Montuschi P.Fuso L, et al.Curr Med Chem. 2013;20(12):1477-95. doi: 10.2174/0929867311320120003.Curr Med Chem. 2013.PMID:23409722Review.
- Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Dual Therapy in a Primary Care Setting in England.Requena G, Banks V, Czira A, Wood R, Tritton T, Wild R, Compton C, Duarte M, Ismaila AS.Requena G, et al.Int J Chron Obstruct Pulmon Dis. 2022 Aug 10;17:1781-1795. doi: 10.2147/COPD.S365480. eCollection 2022.Int J Chron Obstruct Pulmon Dis. 2022.PMID:35983168Free PMC article.
Cited by
- A Review on Asthma and Allergy: Current Understanding on Molecular Perspectives.Gohal G, Moni SS, Bakkari MA, Elmobark ME.Gohal G, et al.J Clin Med. 2024 Sep 27;13(19):5775. doi: 10.3390/jcm13195775.J Clin Med. 2024.PMID:39407835Free PMC article.Review.
- Pharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets.Yates JR.Yates JR.Subst Abuse Rehabil. 2024 Aug 30;15:125-161. doi: 10.2147/SAR.S431273. eCollection 2024.Subst Abuse Rehabil. 2024.PMID:39228432Free PMC article.Review.
- Appraisal of β-Blocker Use in Patients with Cardiovascular Disease and Chronic Obstructive Pulmonary Disease.Xue R, Liu C, Yu Q, Dong Y, Zhao J.Xue R, et al.Am J Cardiovasc Drugs. 2025 Apr 19. doi: 10.1007/s40256-025-00732-1. Online ahead of print.Am J Cardiovasc Drugs. 2025.PMID:40252175Review.
- The Current Molecular and Cellular Landscape of Chronic Obstructive Pulmonary Disease (COPD): A Review of Therapies and Efforts towards Personalized Treatment.Farrell LA, O'Rourke MB, Padula MP, Souza-Fonseca-Guimaraes F, Caramori G, Wark PAB, Dharmage SC, Hansbro PM.Farrell LA, et al.Proteomes. 2024 Aug 16;12(3):23. doi: 10.3390/proteomes12030023.Proteomes. 2024.PMID:39189263Free PMC article.Review.
- Chromium and formoterol therapy for obesity-induced asthma in rats.Ibrahim RT, Moustafa YM, Alwaili MA, Alrebdi AN, Alharthi A, Noufal NR, Khodeer DM.Ibrahim RT, et al.Front Pharmacol. 2025 Apr 2;16:1537022. doi: 10.3389/fphar.2025.1537022. eCollection 2025.Front Pharmacol. 2025.PMID:40242447Free PMC article.
References
- Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2020. - PubMed
Publication types
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources